In 2018, CellCentric announced that it had raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate CCS1477 to treat prostate cancer. The funds were from existing investor, Morningside Venture Investments.
Other earlier research funding came from Providence Investment Company, Takeda Ventures, UK Innovation Science & Seed Fund, Avlar, NESTA and the University of Cambridge.
CellCentric has also benefited from significant non-dilutive financial awards, including from UKRI/InnovateUK’s Biomedical Catalyst programme.
CellCentric’s first-in-class p300/CBP inhibitor is being tested in patients under the leadership of Prof Johann de Bono, at The ICR, Royal Marsden Hospital.
CellCentric was co-founded with one of the pioneers of epigenetic research, Professor Azim Surani FRS CBE of the Gurdon Institute, University of Cambridge. Profesor Surani discovered and described an epigenetic code, beyond DNA, that could be inherited and instruct cell fate.